ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
RespireRx Pharmaceuticals Inc (PK)

RespireRx Pharmaceuticals Inc (PK) (RSPI)

0.0012
0.0001
(9.09%)
Closed March 02 04:00PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

RSPI News

Official News Only

RSPI Discussion

View Posts
TRAPPER JIM TRAPPER JIM 4 hours ago
We’re getting closer sharky. RSPI gonna be great
👍️0
NeutrinoKid NeutrinoKid 8 hours ago
I found useful to try to understand what kept RSPI RespireRX (originally CRTX Cortex or similar) afloat since 1987. Here’s a tidy summary:

Co-founded with (deceased) Nobel laureate Eric Kandel.

Originally focused on the promise of molecules acting on the “AMPA” receptor, the main receiver of neurotransmitters in the brain, in particular for “excitation”, “positive”, “yes” signals.

This was an obvious target for potential new pharmaceuticals, but it turned out when you messed with it the result could be explosive. Compound with a potent specificity to AMPAR tended to muck the brain up i.e. triggering seizures, or shutting down breathing, etc.

So the candidates for drugs started as low-potency, requiring large amounts dose-wise, not getting in the right tissues easily. There were issues with poor absorption, delivery, metabolism, because natural chemicals that “pushed that button” were often poisons.

Thus attempts to modulate on AMPAR directly have floundered, but the principle indeed remained on the back of scientists’ minds and the patents for “AMPAkine drugs” was good for a long time. So the company redirected their efforts to find “loopholes”, to enhance drug delivery, such as “nanoparticules” to “smuggle” drugs to places where they normally would not go.

The “nanoparticles” could be used to smuggle many other molecules, which led to a strategy of diversifying the portfolio of drugs that we see, in a rather attractive umbrella of mutually interlocked IPs. So we have development with quite powerful foresight here, folks.

And doing all of this is hard work, very challenging, and open to be set aside by “short-termist” interests. And in the end it has to actually work! So that’s it.
👍️ 1
LTListener LTListener 9 hours ago
lol. not sure how well thoughts are being expressed. Just thinking it would not take much to see this trade around a nickel and at a good speculative valuation while progress is initiated on both the OSA and epilepsy/pain drug programs hopefully unlocking further value.
👍️0
jacksonjohn jacksonjohn 11 hours ago
Jeff not happy about the volume. -J
👍️0
jacksonjohn jacksonjohn 11 hours ago
Jeff not happy about the volume. -J
👍️0
Dj56 Dj56 13 hours ago
Thanks for expressing the bigger picture very well


...[.and not beginning by drawing a picture of the infinite universe and from there narrowing your focus in stages like Goèthe...😁]
👍️0
LTListener LTListener 13 hours ago
First time caller, long time listener...

Really feels like this pharma is close to rectifying the imbalance between market cap and valuation/potential. On one hand you have the messy financials, some convertible debt/conversions, a lost at sea type slow motion for progress. On the other hand you have not 1 but multiple positive and lucrative drug pipelines which feel close to action.

The OSA drug in final stages and according to their presentation is ready to manufacture the new formulations leading into trials while launching the new company on the ASX exchange with a valuation 20+ million. NONE of that appears exhibited in current market cap of RSPI. Seems like with a chunk of financing in place a logical approach to clinicals and massive potential upon successful trials, there is a big disconnect in how truly valuable an OSA drug would be in the marketplace and the current market cap of RSPI.

Only can imagine the threat of convertibles/conversions holding this back. Seems like the new VP may be tasked with this clean up and the recent 8-k highlighting an institutional investor taking over a chunk of convertible debt at very company favorable terms is IMO a strong indicator that clean up is well in motion and I would expect further institutional support coming. If they can clear out convertibles then possibly they could acquire the funding/partnership necessary to conduct the preclinical IND studies for epilepsy/pain which are extremely promising which one would think garner some equity interests from larger fish as well.

All-in-all, seems a no brainer to accumulate here at under 1 million in valuation. Heck under 10 million in valuation would still accumulate given the underserved needs of both very promising drugs in development and likely any potential success yieldeing value well into the 100's of millions for the development efforts.

good luck to development team to meet these patient needs as well as us investors.

👍️ 1
georgeofthebungle georgeofthebungle 15 hours ago
Filled some 11’s
👍️0
sharky sharky 15 hours ago
Nice find at Walmart. I'll ask for it next time I go. https://www.blinkhealth.com/marinol


$RSPI
👍️0
TRAPPER JIM TRAPPER JIM 1 day ago
Looks like you can buy in through Walmart 60 tablets for $378.59 https://www.blinkhealth.com/marinol
👍️0
TRAPPER JIM TRAPPER JIM 1 day ago
Just looking into their drug Drabinol which is already FDA approved for other uses in the States.

Dronabinol is already approved in the United States by the FDA for other indications, anorexia associated with AIDS and chemo-therapy induced nausea and vomiting. It is a Schedule III drug (low risk of abuse) and is Medicare Part B reimbursed for its current indications.
https://www.respirerx.com/development/index.html#:~:text=Dronabinol%20is%20already%20approved%20in,reimbursed%20for%20its%20current%20indications.
👍️0
TRAPPER JIM TRAPPER JIM 1 day ago
Right on sharky. RSPI moving forward. Heres a link with some more info about ResolutionRx the subsidiary company. https://www.resolutionrx.com.au/company-overview
👍️0
jacksonjohn jacksonjohn 1 day ago
Jeff says just bring on the buyers he will help with the supply issue.
😂 1
fly_fisherman fly_fisherman 2 days ago
Very Optimistic Here

Market Cap: 792,799 (Dirt Cheap) Just Saying Market Cap at 10 million = PPS: .0143
I know some believe it would be much higher than that on a buyout. Just displaying some what-ifs. Nobody will complain if its higher👍️

Partnership/Sale/Funding being sought & can happen at any time. Updates like this will send this undervalued pharma up with a vengeance imho!👍

Patience!
👍️ 2 💯 1
sharky sharky 2 days ago
Phase III approaching product pipeline: https://respirerx.com/product-pipeline/


$RSPI
👍️0
ace65 ace65 2 days ago
Good..lol.Maybe no more sellers down here.
👍️0
georgeofthebungle georgeofthebungle 2 days ago
I didn’t. Had a bid in at 11 most of the day
👍️0
ace65 ace65 2 days ago
Did you get any on the bid?
👍️0
fly_fisherman fly_fisherman 2 days ago
Loaded with Patience👍️

Game/Life Changer in the making!

Oversold, getting ready to turn up👍️
👍️ 2 💯 2
georgeofthebungle georgeofthebungle 3 days ago
Bidding here
👍️0
TRAPPER JIM TRAPPER JIM 3 days ago
Right on sharky.
👍️ 1
TRAPPER JIM TRAPPER JIM 3 days ago
Sure looks like it
👍️ 1
Dj56 Dj56 3 days ago
Does anyone have any concrete facts one way or the other regarding whether rspi has more gravitas as a potential winning stock only by virtue of being affiliated with in the NIH initiative?
👍️0
Tazmanian1640 Tazmanian1640 4 days ago
RSPI - SOON will be 0002
💯 1
sharky sharky 4 days ago
$RSPI KRM-II-81, a GABAA receptor potentiator, is being developed to provide pain relief without the harmful side effects commonly associated with opioids.

Meanwhile, the NIH HEAL Initiative is a comprehensive response to the opioid crisis launched in April 2018, aiming to improve prevention, treatment, and pain management strategies.

“We are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research,” said Dr Jeffrey Witkin, a senior research fellow with RespireRx.

As well as pain relief, KRM-II-81 has shown promising results in treatment-resistant epilepsy models and human translational studies, thereby positioning it as a versatile candidate for addressing a range of neurological disorders.
👍️ 1
jacksonjohn jacksonjohn 4 days ago
We need Dr. Zino to come back. He was good at moving supply.
👍️0
ace65 ace65 4 days ago
Is it safe to say its bottomed out finally?
😂 1
Dj56 Dj56 4 days ago
They have yet to.do any clinicals
👍️0
LEFTY1182 LEFTY1182 4 days ago
It should be good for .05+ imo
👍️0
ArcherNebula41 ArcherNebula41 4 days ago
This is good in theory...
But as we all know, it's theory.
In RSPIs case, if in fact this were true to form, then we wouldn't be at 0012.
There is more than meets the eye with this stock..
👍️0
TRAPPER JIM TRAPPER JIM 4 days ago
Yes sir. RSPI gonna be great
👍️ 1
DTGoody DTGoody 4 days ago
We're getting Close Jim!
👍️0
TRAPPER JIM TRAPPER JIM 4 days ago
Evening sharky. Selling slowing up today. Bring on the bounce RSPI
👍️ 1
oldstocks oldstocks 4 days ago
Jeff you will have to be happy with the ones that already bought and are holding a lot of shares

To many others have news or no news and running

Jeff you need to make things exciting
👍️0
oldstocks oldstocks 4 days ago
How to calculate the value of drugs and biotech companies

https://www.baybridgebio.com/drug_valuation.html
👍️ 1
jacksonjohn jacksonjohn 4 days ago
Who is not being a team player and not buying here. Jeff not happy - J
👍️0
Xtremetz1 Xtremetz1 5 days ago
As I posted before. The purchase price for this company will never be 10 million dollars. This company if sold for that price would loose money. The testing process to bring a drug through the different phases is a lot more than 10 mil. Try more like 10 times that amount. The usual multiplier for the value of a successful Bio is about 30 times. I'm guessing the multiplier varies based on market potential of the drug and how much of a need/market there is for that drug.
👍️0
jacksonjohn jacksonjohn 5 days ago
Patience is paying here! - Jeff and friends
👍️0
waterpro42 waterpro42 5 days ago
Patience will pay here!
👍️0
fly_fisherman fly_fisherman 5 days ago
Companies Now Reaching 1T Valuations

$RSPI with 2 groundbreaking drugs in the pipeline among many others is priced for peanuts.

Market Cap Market Cap $726,732 02/23/2024 Patented/IP with very promising results known today makes it work much more!

Multi purpose drug in underserved markets. Much needed Opioid alternative, early groundbreaking results for Epilepsy plus other neuropsychiatric disorders!

Some pharma is going to come along and scoop this company up for 5-10 million easy! Worth much more! Doesn't even need to be a big one.

I will be here👍️
👍️0
fly_fisherman fly_fisherman 5 days ago
GM Fellow RSPI Investors!

Have a super day!👍️
👍️0
sharky sharky 5 days ago
Good morning, 50dma at .0013, 200dma at .0016, RSI at 41.08 on daily chart.


$RSPI
👍️0
ArcherNebula41 ArcherNebula41 5 days ago
This is truly a POS ...
Again, us longs are must be stupid....
It's always, keep buying..one day it will run..
One day, one day, one day....over and over..
Truly a POS stock..
😂 1 🤡 1
jacksonjohn jacksonjohn 5 days ago
It usually happens, but sometimes it takes a long time, I had to hold it for a long time before it finall ran.
The pump will come, I'm just afraid that they could do a RS to start the cycle all over again.
👍️0
TRAPPER JIM TRAPPER JIM 6 days ago
I just keep adding and waiting for the big bounce
👍️ 1
jacksonjohn jacksonjohn 6 days ago
Patience you will get your .0011, .0010, .... etc.. all orders will be filled - J
👍️0
StocktonCA StocktonCA 1 week ago
lots of volume, lots of sells=conversions or dilution. bottom line = pretty crappy SP.

Would be nice to see some further updates
👍️ 1
TRAPPER JIM TRAPPER JIM 1 week ago
Have a good weekend sharky
👍️0
georgeofthebungle georgeofthebungle 1 week ago
Bidding more
👍️0
sharky sharky 1 week ago

RespireRx's key asset moves to next stage of NIH initiative
RespireRx's key asset moves to next stage of NIH initiative
Proactive Investors

Published Feb 13, 2024 09:20

Updated Feb 13, 2024 10:15

RespireRx's key asset moves to next stage of NIH initiative
Proactive Investors - RespireRx Pharmaceuticals (OTC:RSPI) Inc, a pioneer in the field of neuronal signaling treatments, said its lead compound, KRM-II-81, has progressed to the next evaluation phase of the National Institutes for Health's HEAL Initiative's Preclinical Screening Platform for Pain (PSPP) program.

In doing so the compound demonstrated efficacy in reducing pain-like behaviors in rat models, covering both male and female subjects across various pain measures, underlining its potential to treat acute, chronic, and neuropathic pain without leading to tolerance or sedation.

KRM-II-81, a GABAA receptor potentiator, is being developed to provide pain relief without the harmful side effects commonly associated with opioids.

Meanwhile, the NIH HEAL Initiative is a comprehensive response to the opioid crisis launched in April 2018, aiming to improve prevention, treatment, and pain management strategies.

“We are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research,” said Dr Jeffrey Witkin, a senior research fellow with RespireRx.

As well as pain relief, KRM-II-81 has shown promising results in treatment-resistant epilepsy models and human translational studies, thereby positioning it as a versatile candidate for addressing a range of neurological disorders.

https://m.ca.investing.com/news/stock-market-news/respirerxs-key-asset-moves-to-next-stage-of-nih-initiative-3262753

$RSPI
👍️ 2

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com